We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lifeline Sci | LSIC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 308.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 308.50 | 308.50 |
| Top Posts |
|---|
Posted at 24/11/2016 17:24 by toyin trier1They are not aloud to do that, LSIC will use the exchange rate printed in the FT on the day it happens so your broker will not be involved with exchange rates. All the best |
Posted at 15/9/2016 15:22 by somerset lad From pp. 36 and 37 of the Shareholder Circular:"In addition to an increase in Mr. Kravitz’s base salary from $390,000 to $440,000 (which is Mr. Kravitz’s first salary increase in five years), such agreement provides for the potential to earn bonuses of up to $700,000 upon achievement of certain milestones and eligibility for annual “stretch” I too would like to benefit from the growth I expect and will therefore be voting against the proposal to delist, as I believe it is in the better interests of shareholders for LSIC to remain independent and list on Nasdaq. |
Posted at 02/9/2016 11:30 by sharesurfer22 They are getting this company at an absolute steal. I would have much preferred no takeover at all unless it was a massive premium. There are so few companies that have a real niche in a growing market (with potential for selling into new markets). All this and trading at an undemanding valuation. I would happily have held for years and years. I had high hopes this could be a 10 bagger.If there was no takeover, the price could have risen another 15% today. The management team at LSIC should be shot for selling this gem of a company for a song. What is the likelihood of a counter bid from someone else? Or is this a done deal? |
Posted at 02/9/2016 11:20 by interceptor2 I have now sold all of my holdings, first batch went at 300p at the open, then I had to wait for the price to come back and sold in two further transactions at 285p and 290p. So on average I was down just 6% from the offer price, I would rather reinvest the cash elsewhere with a the probability that I can make over 5% before December in another opportunity. Overall LSIC was a good investment from December last year, just a shame it didn't end a little better. |
Posted at 02/9/2016 08:45 by modform EM, I recall you bought LSIC in the eezymoney pf, in the hope of a better deal, I trust you haven't sold any yet. To sell at 260, it's just crazy |
Posted at 02/9/2016 08:37 by eezymunny Always makes me laugh when peeps so upset about a t/o price. I mean you tout the company about, and see who is willing to pay most. It is what it is. We'd all prefer a higher price but we're all greedy mugs for thinking we'd get one, no?I note that LSIC products are already on the Genext website. FWIW! |
Posted at 23/6/2016 08:46 by glasshalfull LSIC don't regularly release an AGM statement...I certainly wasn't expecting one this morning.With potential ramifications following today's referendum, I believe it prudent that the company wait until next week to ensure all factors considered. Regards GHF |
Posted at 16/2/2016 14:49 by interceptor2 Pleased to see these slowly creep up, even more impressive against the nervous market backdrop. There has been constant small scale buying here in the last few weeks.Panmure Gordon still have LSIC under review, shame that can't be bothered to give some market estimates. |
Posted at 22/9/2015 02:47 by rambutan2 To accompany today's good interims ( )...21 September 2015 Lifeline Scientific, Inc. ("Lifeline" or the "Company") Strategic review Lifeline set to explore strategic and financial alternatives aimed to increase shareholder value Lifeline Scientific (AIM: LSIC), the transplantation technology company, announces that its Board of Directors has determined to explore a full range of strategic and financial alternatives to enhance shareholder value, and the Company has retained Piper Jaffray to assist in the process. The Board believes that the Company is at an inflection point in its growth, and that opportunities represented by its existing business combined with China's Food and Drug Administration (CFDA) approvals of LifePort Kidney Transporter and related single-use consumables and solutions, recent progress in Brazil and the prospects of LifePort Liver Transporter, are not reflected in the Company's current market value. Consequently the Board plans to explore a range of options, which could include (though will not be limited to), a strategic merger, strategic acquisitions, a potential sale of the Company, and a potential listing of the Company's shares on the NASDAQ market. Commenting David Kravitz, CEO of Lifeline Scientific, said: "Our board is focused on maximising shareholder value in this time of significant opportunity within the global transplant market. Accordingly, we will thoroughly explore the full range of strategic and financial alternatives available to capitalise on our market-leading platform of LifePort based organ recovery and preservation products, and our premium global brand. All options will be thoroughly reviewed and we will take the time we require to evaluate our opportunities, and achieve the best results for our shareholders, business partners and associates." The Board is at the beginning stage of its strategic and financial review, and no assurance can be given as to its outcome or timing. The Company does not presently intend to make any further public comment regarding the review unless and until the board approves the outcome of the review. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
